Hemofília: vizsgálatok itt: Svédország
8 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. november 11.. Ask the study team whether a trial fits you.
- 3. fázisTaking peopleA Non-Investigational Product, Multi-Center Cohort Study to Describe Long-Term Safety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec
- Where
- Malmö
- Életkor
- 18 év to 64 év
- People
- 32 worldwide
- Run by
- Pfizer Inc.
See details and how to join2025-523660-21-00 · EU 2025-523660-21-00 - 3. fázisTaking peopleSafety and Effectiveness of Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec in Patients With Hemophilia A or B Respectively
- Where
- Malmö
- Életkor
- 18 év and over
- People
- 173 worldwide
- Run by
- Pfizer
See details and how to joinNCT05568719 - 4. fázisTaking peopleTreatment of Hemophilia A Patients With FVIII Inhibitors
- Where
- Malmo
- People
- 120 worldwide
- Run by
- Emory University
See details and how to joinNCT04023019 · EU 2024-516741-39-00 - 1. fázisTaking peopleA Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia A
- Where
- Malmo, Solna
- Életkor
- 18 év to 64 év
- People
- 30 worldwide
- Run by
- Novo Nordisk A/S
See details and how to joinNCT07220564 · EU 2025-520490-38-00 - No phaseTaking peopleThe European Paediatric Network for Haemophilia Management ( PedNet Registry)
- Where
- Malmö, Stockholm
- People
- 4000 worldwide
- Run by
- PedNet Haemophilia Research Foundation
See details and how to joinNCT02979119 - No phaseTaking peopleGlobal Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors
- Where
- Solna
- Életkor
- 7 év and over
- People
- 20
- Run by
- Karolinska Institutet
See details and how to joinNCT02453542 - 2/3. fázisCsak meghívásosLong-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
- Where
- Malmo
- Életkor
- 18 év and over
- People
- 56 worldwide
- Run by
- CSL Behring
See details and how to joinNCT05962398 · EU 2023-503765-37-00 - 1. fázisTaking peopleThis is a first in human study, in patients with severe bleeding disorder (hemophilia A), who has developed inhibitory antibodies against coagulation factor VIII.The aim is to study the safety and efficacy of dendritic cells, originating from the patient itself. The dendritic cells has been loaded with coagulation factor VIII for an improved immunological tolerance. (TOLER8)
- Where
- Lund
- Életkor
- 18 év to 64 év
- People
- 4 worldwide
- Run by
- Cell4Cure AB
See details and how to join2022-502030-12-01 · EU 2022-502030-12-01